scorecardresearch
Add as a preferred source on Google
Friday, December 12, 2025
TopicNovo Nordisk

Topic: Novo Nordisk

In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Eli Lilly announces trial results for world’s 2nd weekly insulin, aims for launch by year-end

New Delhi: There is excitement and hope in the insulin market the world over after U.S. based pharma giant Eli Lilly & Company on...

Ozempic on steroids? Successor that could cut down weight in half the time coming soon

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.

On Camera

IndiGo cancellations made TV news do the unexpected — question the Modi government

Republic TV was the harshest of them all: “The (civil aviation) minister has done a bad job,” said prime time anchor Arnab Goswami.

IndiGo’s profits dipped, most airlines sunk into losses last fiscal even as flier numbers soared

Despite growing passenger volume, 11 out of 14 carriers reported losses in 2023-24. IndiGo recorded profit of Rs 8,167 crore, which reduced to Rs 7.253 crore in 2024-25.

Dubai Tejas crash revives focus on advanced, fully automated safety systems

Dubai airshow crash & pilot death have rekindled concerns over pilot safety, and need for smarter automated systems that can step in when G-forces, temporary loss of consciousness hit the pilot.

Asim Munir & Pakistan’s Failed Marshal Doctrine

None of Pakistan’s PMs has lasted 5 years. That the current PM has given Asim Munir 5 years shows that of all military dictatorships history has seen, Pakistan’s is most creative.